1. The Psychiatrist's Role in Tardive Dyskinesia

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. What Is TD?

5. Risk of TD With Antipsychotics

6. Risk Factors for TD

7. Preventing TD

8. Monitoring for Movement Disorders

9. Differential Diagnosis of TD

10. Initial Management of TD

11. Issues for Patients With Schizophrenia

12. Evidence for Various Therapies

13. VMAT2

14. Tetrabenazine

15. Valbenazine

16. KINECT 3: Phase 3 Trial of Valbenazine

17. Deutetrabenazine

18. Phase 3 Trials of Deutetrabenazine

19. Summary: Deutetrabenazine and Valbenazine

20. Takeaway Points

21. Abbreviations